SMLR - Is Semler Scientific Stock Still a Buy After Its Earnings Miss?
Shares of Semler Scientific (NASDAQ: SMLR) -- a medical device software company providing innovative software for peripheral artery disease (PAD) testing -- fell 25% after the company disappointed investors in its third-quarter earnings. For those unfamiliar, Semler Scientific is redefining how PAD -- a disease that blocks arteries and reduces blood flow to extremities -- is tested by making it easier to get a PAD test. PAD is severely underdiagnosed -- only 2 million people are diagnosed yearly, though Semler estimates that 20 million Americans could have PAD. The reason it is underdiagnosed is that it is difficult and time-consuming to get a PAD test, but Semler is looking to change that.
These results came after the company missed estimates and its growth slowed but is this a red flag for investors? Here's everything you need to know about Semler's third quarter, and whether or not you should be buying the dip today.
Image source: Getty Images.
For further details see:
Is Semler Scientific Stock Still a Buy After Its Earnings Miss?